Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plus Therapeutics (PSTV) Amortization of Deferred Charges (2016 - 2024)

Plus Therapeutics (PSTV) has disclosed Amortization of Deferred Charges for 15 consecutive years, with $4000.0 as the latest value for Q2 2024.

  • On a quarterly basis, Amortization of Deferred Charges fell 92.45% to $4000.0 in Q2 2024 year-over-year; TTM through Dec 2024 was $20000.0, a 89.47% decrease, with the full-year FY2024 number at $20000.0, down 89.47% from a year prior.
  • Amortization of Deferred Charges was $4000.0 for Q2 2024 at Plus Therapeutics, down from $16000.0 in the prior quarter.
  • In the past five years, Amortization of Deferred Charges ranged from a high of $156000.0 in Q4 2020 to a low of $4000.0 in Q2 2024.
  • A 5-year average of $88933.3 and a median of $91000.0 in 2022 define the central range for Amortization of Deferred Charges.
  • Peak YoY movement for Amortization of Deferred Charges: skyrocketed 71.91% in 2020, then plummeted 92.45% in 2024.
  • Plus Therapeutics' Amortization of Deferred Charges stood at $156000.0 in 2020, then decreased by 3.21% to $151000.0 in 2021, then plummeted by 47.02% to $80000.0 in 2022, then tumbled by 62.5% to $30000.0 in 2023, then crashed by 86.67% to $4000.0 in 2024.
  • Per Business Quant, the three most recent readings for PSTV's Amortization of Deferred Charges are $4000.0 (Q2 2024), $16000.0 (Q1 2024), and $30000.0 (Q4 2023).